Literature DB >> 23188824

Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines.

Steffan Vartanian1, Carolyn Bentley, Matthew J Brauer, Li Li, Senji Shirasawa, Takehiko Sasazuki, Jung-Sik Kim, Pete Haverty, Eric Stawiski, Zora Modrusan, Todd Waldman, David Stokoe.   

Abstract

To assess the consequences of endogenous mutant K-Ras, we analyzed the signaling and biological properties of a small panel of isogenic cell lines. These include the cancer cell lines DLD1, HCT116, and Hec1A, in which either the WT or mutant K-ras allele has been disrupted, and SW48 colorectal cancer cells and human mammary epithelial cells in which a single copy of mutant K-ras was introduced at its endogenous genomic locus. We find that single copy mutant K-Ras causes surprisingly modest activation of downstream signaling to ERK and Akt. In contrast, a negative feedback signaling loop to EGFR and N-Ras occurs in some, but not all, of these cell lines. Mutant K-Ras also had relatively minor effects on cell proliferation and cell migration but more dramatic effects on cell transformation as assessed by growth in soft agar. Surprisingly, knock-out of the wild type K-ras allele consistently increased growth in soft agar, suggesting tumor-suppressive properties of this gene under these conditions. Finally, we examined the effects of single copy mutant K-Ras on global gene expression. Although transcriptional programs triggered by mutant K-Ras were generally quite distinct in the different cell lines, there was a small number of genes that were consistently overexpressed, and these could be used to monitor K-Ras inhibition in a panel of human tumor cell lines. We conclude that there are conserved components of mutant K-Ras signaling and phenotypes but that many depend on cell context and environmental cues.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23188824      PMCID: PMC3554910          DOI: 10.1074/jbc.M112.394130

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Regulation of ras signaling dynamics by Sos-mediated positive feedback.

Authors:  Sean Boykevisch; Chen Zhao; Holger Sondermann; Polyxeni Philippidou; Simon Halegoua; John Kuriyan; Dafna Bar-Sagi
Journal:  Curr Biol       Date:  2006-11-07       Impact factor: 10.834

2.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival.

Authors:  Anurag Singh; Patricia Greninger; Daniel Rhodes; Louise Koopman; Sheila Violette; Nabeel Bardeesy; Jeff Settleman
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

Review 3.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Authors:  Helena Linardou; Issa J Dahabreh; Dimitra Kanaloupiti; Fotios Siannis; Dimitrios Bafaloukos; Paris Kosmidis; Christos A Papadimitriou; Samuel Murray
Journal:  Lancet Oncol       Date:  2008-09-17       Impact factor: 41.316

4.  Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.

Authors:  Jihye Yun; Carlo Rago; Ian Cheong; Ray Pagliarini; Philipp Angenendt; Harith Rajagopalan; Kerstin Schmidt; James K V Willson; Sandy Markowitz; Shibin Zhou; Luis A Diaz; Victor E Velculescu; Christoph Lengauer; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos
Journal:  Science       Date:  2009-08-06       Impact factor: 47.728

Review 5.  Hyperactive Ras in developmental disorders and cancer.

Authors:  Suzanne Schubbert; Kevin Shannon; Gideon Bollag
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

6.  Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers.

Authors:  Sabrina Arena; Claudio Isella; Miriam Martini; Ario de Marco; Enzo Medico; Alberto Bardelli
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

Review 7.  Ras oncogenes: split personalities.

Authors:  Antoine E Karnoub; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07       Impact factor: 94.444

8.  Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses.

Authors:  Federica Di Nicolantonio; Sabrina Arena; Margherita Gallicchio; Davide Zecchin; Miriam Martini; Simona Emilia Flonta; Giulia Maria Stella; Simona Lamba; Carlotta Cancelliere; Mariangela Russo; Massimo Geuna; Giovanni Appendino; Roberto Fantozzi; Enzo Medico; Alberto Bardelli
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-23       Impact factor: 11.205

9.  (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.

Authors:  Christine A Pratilas; Barry S Taylor; Qing Ye; Agnes Viale; Chris Sander; David B Solit; Neal Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-27       Impact factor: 11.205

10.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

View more
  38 in total

1.  KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis.

Authors:  Dana Rabara; Timothy H Tran; Srisathiyanarayanan Dharmaiah; Robert M Stephens; Frank McCormick; Dhirendra K Simanshu; Matthew Holderfield
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

2.  The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer.

Authors:  Abdel-Majid Khatib; John W M Creemers; Zongsheng He; Lieven Thorrez; Geraldine Siegfried; Sandra Meulemans; Serge Evrard; Sabine Tejpar
Journal:  Oncogene       Date:  2020-03-06       Impact factor: 9.867

3.  An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.

Authors:  Martin Indarte; Roisin Puentes; Marco Maruggi; Nathan T Ihle; Geoffrey Grandjean; Michael Scott; Zamal Ahmed; Emmanuelle J Meuillet; Shuxing Zang; Robert Lemos; Lei Du-Cuny; Fabiana I A L Layng; Ricardo G Correa; Laurie A Bankston; Robert C Liddington; Lynn Kirkpatrick; Garth Powis
Journal:  Cancer Res       Date:  2019-04-30       Impact factor: 12.701

4.  Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.

Authors:  A Staffas; C Karlsson; M Persson; L Palmqvist; M O Bergo
Journal:  Leukemia       Date:  2014-11-05       Impact factor: 11.528

5.  Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations.

Authors:  Leni S Jacob; Sakari Vanharanta; Anna C Obenauf; Mono Pirun; Agnes Viale; Nicholas D Socci; Joan Massagué
Journal:  Cancer Res       Date:  2015-07-24       Impact factor: 12.701

6.  Network analysis of differential Ras isoform mutation effects on intestinal epithelial responses to TNF-α.

Authors:  Ken S Lau; Sarah B Schrier; Jessica Gierut; Jesse Lyons; Douglas A Lauffenburger; Kevin M Haigis
Journal:  Integr Biol (Camb)       Date:  2013-10-02       Impact factor: 2.192

Review 7.  Therapeutic targeting of RAS: New hope for drugging the "undruggable".

Authors:  Imran Khan; J Matthew Rhett; John P O'Bryan
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2019-10-31       Impact factor: 4.739

8.  Oncogenic KRAS suppresses store-operated Ca2+ entry and ICRAC through ERK pathway-dependent remodelling of STIM expression in colorectal cancer cell lines.

Authors:  Cristina Pierro; Xuexin Zhang; Cynthia Kankeu; Mohamed Trebak; Martin D Bootman; H Llewelyn Roderick
Journal:  Cell Calcium       Date:  2018-03-14       Impact factor: 6.817

9.  KRASG12C inhibition produces a driver-limited state revealing collateral dependencies.

Authors:  Kevin Lou; Veronica Steri; Alex Y Ge; Y Christina Hwang; Christopher H Yogodzinski; Arielle R Shkedi; Alex L M Choi; Dominique C Mitchell; Danielle L Swaney; Byron Hann; John D Gordan; Kevan M Shokat; Luke A Gilbert
Journal:  Sci Signal       Date:  2019-05-28       Impact factor: 8.192

10.  KRAS phosphorylation regulates cell polarization and tumorigenic properties in colorectal cancer.

Authors:  Débora Cabot; Sònia Brun; Noelia Paco; Mireia M Ginesta; Núria Gendrau-Sanclemente; Baraa Abuasaker; Triana Ruiz-Fariña; Carles Barceló; Miriam Cuatrecasas; Marta Bosch; Carles Rentero; Gabriel Pons; Josep M Estanyol; Gabriel Capellà; Montserrat Jaumot; Neus Agell
Journal:  Oncogene       Date:  2021-07-31       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.